FDA confirmed in a recent FDA Type B meeting under RMAT designation that the PROACT 1 Phase 3 study could be sufficient to support a full U.S. regulatory approval of rilparencel; ...

Data were limited for patients with eGFR 60, therefore definitive conclusions on the benefits and risks in this ... for use as an adjunct to insulin therapy for glycemic control in adults with type 1 ...

That’s a problem Emory health providers have already encountered, Erskine said. “I’ll give you an example relative to kidney care, there’s something called the GFR, which is the glomerular filtration ...

消息面上，近日，港股创新药企云顶新耀-B重磅产品——全球首个IgA肾病对因治疗药物耐赋康 (布地奈德肠溶胶囊)NefIgArd III期临床试验的全球开放标签扩展 (OLE)研究，在美国肾脏病协会肾脏周 (ASN Kidney Week 2024)上公布积极数据。研究分析揭示，对于已完成NefIgArd III期的IgA肾病患者，接受耐赋康第二个治疗疗程的IgA肾病患者估算肾小球滤过率 (eGFR ...

通常情况下，对肾脏和营养状况的初步评估以及对其变化的密切监测应成为老年CKD患者营养疗护决策和调整的基础。肾脏功能、营养参数以及风险-收益评估应指导临床决定是优先考虑肾脏问题还是营养功能问题（表1） [1] 。

云顶新耀-B(01952)涨超3%，截至发稿，涨3.31%，报37.4港元，成交额5263.04万港元。 消息面上，近日，港股创新药企云顶新耀-B重磅产品——全球首个IgA肾病对因治疗药物耐赋康(布地奈德肠溶胶囊)NefIgArd III期临床试验的全球开放标签扩展(OLE)研究，在美国肾脏病协会肾脏周(ASN Kidney Week2024)上公布积极数据。研究分析揭示，对于已完成NefIgAr ...

Bristol-Myers Squibb Company ( NYSE: BMY) Guggenheim Securities Inaugural Healthcare Innovation Conference November 11, 2024 10:00 AM ET Samit Hirawat - EVP, Chief Medical Officer, Global Drug ...